Artrinovo

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artrinovo

Property Description
Active ingredient Indometacin (Indomethacin)
Form Capsules, Suppositories
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic (Indole derivative)

What Type of Medicine is Artrinovo?

Artrinovo is a pharmaceutical preparation classified as a potent Nonsteroidal Anti-Inflammatory Drug (NSAID) and an Antirheumatic agent. The core function of this medicine is to provide relief by addressing symptoms related to inflammation, pain, and fever in the body. As a synthetic product containing a potent active substance, it is commonly designated for prescription-only use. The medicine's general purpose is centered on achieving comprehensive control over systemic inflammatory responses and associated discomfort.

Composition and Origin: The Active Role of Indometacin

The efficacy of Artrinovo is derived from its single active ingredient, Indometacin (INN), a key distinguishing factor among NSAIDs. This substance is entirely synthetic and belongs to the distinct chemical class of Indole derivatives. Its mechanism of effect is based on its primary role as a powerful Cyclooxygenase (COX) inhibitor, which limits the synthesis of Prostaglandins, the chemical mediators responsible for transmitting pain and inflammation signals throughout the body. Indometacin possesses pronounced anti-inflammatory, analgesic, and antipyretic properties.

Dosage Forms of Artrinovo

Artrinovo is generally available in two distinct dosage forms: capsules and suppositories. The capsules are formulated for oral administration, facilitating absorption through the gastrointestinal tract. Conversely, the suppositories are designed for rectal administration, offering an alternative route for systemic delivery of the Indometacin. The single-ingredient preparation utilizes standard pharmaceutical bases—such as the capsule material or solid semi-synthetic glycerides for the suppositories—to ensure the controlled and effective release of the active substance. This dual formulation allows for alternative clinical applications based on patient needs.

Regulatory References

  1. Indomethacin: MedlinePlus Drug Information

What side effects are possible with Artrinovo?

Possible Side Effects and Safety Information

Artrinovo, a Non-Steroidal Anti-Inflammatory Drug (NSAID), carries a safety profile with potential risks primarily involving the cardiovascular and gastrointestinal systems, consistent with the drug class. The goal of safety monitoring is to use the lowest effective dose for the shortest duration necessary to mitigate these serious risks.

Serious Adverse Reactions and Safety Warnings

  • Cardiovascular Risk: NSAIDs may increase the risk of serious, and potentially fatal, cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk can occur early in treatment and may increase with higher doses or longer duration of use. The drug is contraindicated for use in the setting of coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Risk: Serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, can occur without warning. These events may be fatal, and the risk is higher in the elderly and in patients with a history of GI disease or those using concomitant medications like corticosteroids or anticoagulants.

Common and Less Frequent Adverse Reactions

System-Organ Class Key Adverse Reactions (Commonly Reported)
Gastrointestinal Dyspepsia, nausea, diarrhea, constipation, abdominal pain, bloating.
Nervous System Headache, dizziness, drowsiness.
General Disorders Fluid retention (edema), which may lead to or worsen hypertension and heart failure.

Safety Restrictions and Contraindications

Artrinovo is generally contraindicated for patients with known hypersensitivity to the drug or who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. It is also contraindicated in patients with active gastrointestinal ulcer/bleeding and severe hepatic impairment. Caution and close medical monitoring are necessary for patients with heart failure, uncontrolled hypertension, kidney or liver impairment, and in the elderly population.

Overdose and Emergency Response

Artrinovo Overdose and When to Seek Help

A suspected overdose of Artrinovo (Indometacin) requires immediate medical attention, as official regulatory information states that a large overdosage can be very harmful to both adult and pediatric populations. Emergency medical help must be sought right away for any suspected exposure beyond the prescribed dose.

The officially documented clinical manifestations of overdose primarily affect the Central Nervous System (CNS) and Gastrointestinal (GI) system. CNS effects may include severe headache, confusion, dizziness, extreme tiredness, and possible seizures. GI toxicity can present as nausea, abdominal pain, diarrhea, and vomiting, which may involve visible blood (hematemesis).

Severe overdosage is classified in regulatory labeling as a condition that may progress to life-threatening outcomes. These severe outcomes include acute renal failure (little or no urine output), coma, and the risk of severe gastrointestinal bleeding.

No specific antidote is known for Indometacin toxicity. Therefore, the management procedures outlined in official prescribing information are symptomatic and supportive. These procedures described in regulatory text may include gastric lavage, administration of activated charcoal, and required continuous monitoring of vital signs, blood tests, and the electrocardiogram (ECG) in a hospital setting.

Therapeutic Uses of Artrinovo

What Artrinovo Treats: Main Uses and Benefits

Artrinovo (Indometacin) is commonly used to help relieve symptoms across key domains driven by inflammation, pain, and fever. It is used for the symptomatic management of conditions characterized by periods of heightened symptoms, including Rheumatoid Arthritis, Ankylosing Spondylitis, moderate to severe Osteoarthritis, and acute gouty arthritis. This medication is generally applied in clinical settings that involve acute or unstable symptom patterns, such as sudden gout flares or localized soft tissue inflammation like tendinitis and bursitis (acute painful shoulder).

This supportive therapy assists with managing symptom clusters that may become intense or disruptive, particularly persistent joint pain, swelling, stiffness, and fever. By managing these manifestations, the medication may assist patients with coping more steadily with difficult episodes and may support general well-being during symptomatic phases. As one common goal of this therapy, it may assist with maintaining functional stability during phases of increased distress or discomfort.

Quick Fact: Support for Symptoms Related to Inflammatory States
Purpose: To provide symptomatic support for the pain, stiffness, and swelling associated with inflammatory arthritides and acute musculoskeletal flares.

Regulatory References

  1. NIH DailyMed: Indomethacin Capsules Official Labeling

Eligibility and Restrictions for Use

Official Eligibility Rules for Artrinovo (Indometacin)

Artrinovo's use is strictly defined by regulatory eligibility rules, primarily based on contraindications and patient status, and is generally intended for adults.

Eligibility Status Excluded Populations (Contraindications)
Absolute Non-Eligibility History of aspirin-sensitive asthma or allergic reactions to other NSAIDs or Indometacin itself. Patients undergoing Coronary Artery Bypass Graft (CABG) surgery. Individuals with active or severe gastrointestinal bleeding or severe heart, renal, or hepatic failure.
Form-Specific Ban For suppositories only: Patients with a history of proctitis or recent rectal bleeding.

Age and Reproductive Restrictions:

  • Pediatric Use: Safety and efficacy for the capsule and suppository forms have not been established in children younger than 14 years of age.
  • Geriatric Use: Older adults require greater care due to increased risks, particularly concerning gastrointestinal or kidney function.
  • Pregnancy: The medication is contraindicated in the third trimester (beginning at 30 weeks gestation) and is restricted between 20 and 30 weeks. Use is not recommended during lactation or for women attempting to conceive.

Conditional Use:

Use is restricted or avoided in patients with advanced renal disease or recent myocardial infarction (MI) unless the potential benefits outweigh the risks of worsening the condition. Caution is required for patients with volume depletion, epilepsy, Parkinsonism, or psychiatric disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Artrinovo (Indometacin), a Nonsteroidal Anti-Inflammatory Drug (NSAID), has officially documented interactions that primarily involve pharmacodynamic interference and pharmacokinetic alterations of co-administered substances. Regulatory documents explicitly restrict co-administration with several substance classes.


Documented Interaction Patterns

Co-administration with medicines that affect hemostasis—such as anticoagulants, antiplatelet agents, SSRIs, or SNRIs—increases the risk of serious gastrointestinal bleeding. Additionally, Indometacin may diminish the antihypertensive effect of drugs like ACE Inhibitors and ARBs, and can reduce the natriuretic effect of Diuretics, an officially recognized pharmacodynamic interaction.

In terms of exposure modification, regulatory data shows that Indometacin can increase the serum concentrations and prolong the half-life of Digoxin, Lithium, and Methotrexate, which is a clinically significant pharmacokinetic outcome. Conversely, chronic co-administration of high-dose Aspirin may decrease Indometacin's blood levels.


Restrictions and Specific Combinations

Administration is contraindicated in the setting of peri-operative pain management for Coronary Artery Bypass Graft (CABG) surgery. The use of alcohol is documented as increasing the risk of gastrointestinal adverse events, including bleeding. Co-administration with other NSAIDs or Diflunisal is also restricted by official labeling due to increased risk of serious adverse events or significant alterations in plasma levels.

Mechanism of Action

The primary action of Indometacin is to affect defined enzyme and regulatory systems within the body at the molecular and physiological level. This mechanism focuses on disrupting a central synthesis pathway involving prostanoid generation.

Non-Selective Inhibition of Prostanoid Synthesis

The primary mechanism involves the non-selective competitive inhibition of the Cyclooxygenase (COX) enzyme complex ( COX-1 and COX-2 isoforms). This molecular action blocks the conversion of arachidonic acid into prostaglandins ( PGE2, PGI2) and thromboxane A2 ( TXA2), which are key lipid mediators. The subsequent cascade results in a reduction of prostanoid-mediated vascular effects and decreased prostanoid-mediated excitation of peripheral neuronal structures.

️ Central Thermoregulatory Pathway Modulation

A distinct, yet related, effect involves the drug's activity in the central nervous system (CNS). By inhibiting COX in the hypothalamus, the drug suppresses the local PGE2 synthesis that regulates the thermoregulatory set point. This action results in the lowering of the hypothalamic thermoregulatory set point, which engages systemic mechanisms for heat release (e.g., vasodilation).

Dosage and Administration Information

How to Use Artrinovo

Standard administration of Artrinovo (Indometacin) follows a structured protocol for its oral capsule and rectal suppository forms. This framework addresses administration routes, dosing frequency, and specific timing requirements.


Administration and Dosing Principles

Administration Scope Details
Route of Administration The medicine is administered orally via immediate-release capsules or rectally via suppositories.
Standard Dosing Schedule Initial doses for chronic conditions (e.g., arthritis) begin at 25 mg two or three times daily. Doses for acute flares (e.g., gout) are typically 50 mg three times daily.
Frequency and Titration The immediate-release form is taken in divided doses daily. For chronic treatment, dosage adjustments of 25 mg or 50 mg are made at weekly intervals.
Dosing Maximum The total daily dose generally should not exceed 150 mg to 200 mg.

Usage Context and Duration

Oral Artrinovo capsules are taken with food, immediately after meals, or with an antacid to help minimize potential irritation. For night pain and morning stiffness, a dose of up to 100 mg (oral or rectal) may be administered at bedtime. The duration of therapy depends on the clinical context.

  • For acute episodes like gout, management involves a rapid reduction in dosage until cessation once the pain is tolerable.
  • For chronic conditions, the goal is to establish the smallest effective dose and maintain it as part of a long-term management plan.

Special Population Rules: Dosing for older adults involves greater care and typically begins with the lowest effective dose due to age-related physiological changes. The medicine is ordinarily not prescribed for children 14 years of age and under for these indications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Artrinovo (Indometacin)


Evidence for Use in Chronic Inflammatory Arthritis

Artrinovo (Indometacin) was evaluated in research exploring conditions marked by chronic inflammation and functional limitations, specifically Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). Research exploring how symptoms change over time included short-term Randomized Controlled Trials (RCTs) and long-term observational settings evaluating daily-life functioning.

Studies monitored outcomes related to physical discomfort, including measurements of joint pain, swelling, and morning stiffness. The research described patterns where these measures changed in the observed populations during the study period. Evidence also examined symptom patterns related to functional capability, primarily related to spinal pain and mobility for AS.

Evidence for Acute Pain and Flares

Research for Artrinovo was evaluated in trials assessing short-term or episodic symptom patterns, particularly for acute gouty arthritis and localized inflammatory states like bursitis and tendinitis. These studies were often conducted during periods of increased symptom activity, focusing on episodes where symptoms become more noticeable.

For acute gouty arthritis, research examined outcomes describing episodic changes, such as the time it took to measure a change in pain severity and the time until signs of acute inflammation were observed to resolve. The findings describe patterns observed in these short-term trials, showing how patient-reported pain scores changed over the study period. For localized inflammation, research describes the changes measured in pain and shoulder function.


Research Gaps and Remaining Uncertainties

The research so far indicates that while it has been evaluated in research exploring these conditions, the available evidence is limited regarding its potential to influence the underlying, progressive course of the disease itself. Studies mainly focus on addressing acute or heightened symptom activity.

A major research gap is the limited long-term data regarding the medicine’s potential to slow the progressive structural damage associated with chronic conditions. The available evidence is primarily focused on measurements related to symptoms. Furthermore, comparative evidence is lacking against the most recently developed non-steroidal and non-analgesic agents, and data for certain demographic or comorbidity-defined populations are still emerging.

Key Studies & References NIH DailyMed: Indomethacin Capsules Official Labeling

Frequently Asked Questions (FAQ)

Common questions about Artrinovo (FAQ)


Q: How quickly can someone expect Artrinovo to start working?

Official product information indicates that the time until a noticeable change is measured depends on the condition being addressed. For acute gout, marked pain reduction may be observed to change within 2 to 4 hours. Response for chronic conditions like rheumatoid arthritis may be observed within 48 hours.

Q: How long does Artrinovo stay in your system after stopping it?

The mean elimination half-life, which measures the time it takes for half of the drug to be cleared from the bloodstream, is estimated to be approximately 4.5 to 7 hours. This measurement is derived from official pharmacokinetic studies.

Q: What does 'contraindication' mean in relation to Artrinovo?

A contraindication refers to any specific condition or situation where the use of a medicine is restricted because it may cause significant harm to the patient. For Artrinovo, these rules are established by regulatory bodies to ensure the medicine is only used when the potential benefits are judged to outweigh these specified risks.

Q: Does Artrinovo have a black box warning from the FDA?

Yes, the official U.S. Food and Drug Administration (FDA) label for Artrinovo includes a Boxed Warning. This warning highlights the risk of serious cardiovascular events, such as heart attack and stroke, and serious gastrointestinal events, including bleeding and ulcers.

Q: What should be done if someone experiences a serious side effect from Artrinovo?

If symptoms of a serious adverse event occur, such as bloody or black stools, vomiting blood, sudden difficulty breathing, or signs of a severe allergic reaction (anaphylaxis), patients are advised to seek emergency medical attention immediately. Patients should report any concerning or unexpected symptoms to their healthcare provider.

Q: What happens if a dose of Artrinovo is missed?

Official guidance indicates that a missed dose may be taken as soon as it is remembered. However, if the time for the next scheduled dose is approaching, the missed dose should be skipped. In this instance, it is generally recommended not to take a double dose.

Q: Can Artrinovo be taken with vitamins or supplements?

Regulatory information indicates a risk of interaction between Artrinovo and certain supplements, such as potassium. These combinations may lead to increased levels of potassium in the blood. It is necessary to consult a healthcare professional about any vitamins or supplements under consideration.

Q: Are there any known interactions between Artrinovo and herbal remedies?

Official documentation indicates that certain herbal products, including ginkgo biloba and white willow bark, may interact with Artrinovo. These interactions could increase the risk of bleeding or other adverse effects. Regulatory guidelines emphasize the importance of consulting a healthcare professional before use.

Q: Is Artrinovo safe to take long-term?

Official regulatory guidance for Artrinovo, consistent with its class, recommends using the lowest effective dosage for the shortest duration necessary. This strategy is advised to help manage the potential risk of serious side effects that may occur with extended use.

Q: Can people with high blood pressure safely use Artrinovo?

Official labeling indicates that Artrinovo may cause fluid retention and may also reduce the effectiveness of some blood pressure medications. For individuals with existing high blood pressure, close medical monitoring is required to manage these potential effects during treatment.

Q: How do doctors monitor the effects of Artrinovo?

To help manage potential risks, official information recommends that doctors monitor certain factors during treatment. Monitoring may include the periodic assessment of blood pressure, checking for signs of fluid retention, and evaluating kidney (renal) and liver function, particularly for specific patient groups.

Q: Are there any specific lifestyle changes recommended while using Artrinovo?

Official patient leaflets note that this medicine can lead to sodium and water retention in the body. Due to this potential effect, official guidance suggests that reducing dietary salt intake may be recommended by a healthcare professional.

Q: Can someone stop taking Artrinovo abruptly?

Patient information advises users to continue taking the medicine exactly as prescribed. Official patient information indicates the medicine should generally not be stopped unless a healthcare professional advises discontinuation.

Q: Are there specific tests needed before starting Artrinovo?

Before prescribing Artrinovo, a healthcare provider typically conducts a baseline health assessment. This assessment helps check for any pre-existing conditions, such as heart, kidney, or liver problems, that may require monitoring. This initial assessment may involve specific laboratory tests.

Q: Does Artrinovo cause weight gain or loss?

The official adverse reactions list for Artrinovo includes fluid retention, also known as edema. This condition can cause swelling, primarily in the legs, arms, or feet.

Q: Are there any foods that should be specifically avoided while taking Artrinovo?

Official regulatory sources do not list specific food prohibitions that must be strictly avoided. However, because Artrinovo has the potential to cause fluid retention, official guidance suggests that reducing dietary salt intake may be recommended by a healthcare professional.

How should Artrinovo be stored and disposed of?

Storage and Handling Requirements

Storage conditions for Artrinovo (Indometacin) are dependent on the dosage form to maintain product stability and integrity, as required by regulatory labeling.

Dosage Form Mandatory Storage Condition
Capsules (Oral) Store at controlled room temperature (20 C to 25 C). Keep away from heat, moisture, and do not freeze.
Suppositories (Rectal) Store in the refrigerator (2 C to 8 C) to maintain the solid form. Keep away from excessive heat and light.

Both dosage forms must be kept in their original, closed container to protect them from light and moisture. A mandatory requirement is to always store Artrinovo out of the sight and reach of children and pets.

Disposal

Unused or expired Artrinovo should not be disposed of in household trash or wastewater. Patients must consult a healthcare professional or local waste management program for the official guidance on how to safely dispose of the medicine according to local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artrinovo found in:

A-Z Index: